Tokyo, Nov. 16 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063629) titled 'RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study' on Nov. 16.

Study Type: Observational

Primary Sponsor: Institute - Nagoya City University

Condition: Condition - Systemic rheumatic diseases treated with anti-inflammatory and immunomodulatory agents Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The aim of this study is to establish a multicenter registry using electronic health record data from patients with systemic rheumatic diseases and to continuously evaluate treatment patterns, clinical outcomes, and the safety of anti-inflammatory and immunomodulatory therapies in real-world clinical practice. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - Not applicable Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients meeting all of the following criteria will be included in the analysis: 1. A history of outpatient visits to, or hospitalization under the primary or secondary care of, a rheumatology and connective tissue disease department at a participating institution. 2. A diagnosis of a systemic rheumatic disease, regardless of whether the relevant classification criteria are fulfilled. 3. Initiation of anti-inflammatory and immunomodulatory therapy for the purpose of controlling disease activity after the start of electronic health record operation at each participating institution. Key exclusion criteria - Patients who meet either of the following criteria:

Patients who were not registered in this study and visited the study institution 15 or more days after initiation of anti-inflammatory or immunomodulatory treatment for disease activity control of systemic rheumatic diseases at another medical institution, and who meet either of the following conditions: (a) Patients with no history of hospitalization in the Department of Rheumatology and Clinical Immunology (or equivalent department) at the study institution, and who had either three or fewer actual outpatient visit days in that department or an observation period of less than 100 days, with no occurrence of death or adverse events by the time of the last observation.

(b) Patients for whom the diagnostic evidence, date of treatment initiation, treatment details (including the history of anti-inflammatory or immunomodulatory drug use and the initial dose of glucocorticoids), or history of disease relapse cannot be confirmed from the provided medical records or other clinical information. Target Size - 7500

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2026 Year 04 Month 14 Day Date of IRB - 2026 Year 04 Month 24 Day Anticipated trial start date - 2026 Year 04 Month 24 Day Last follow-up date - 2036 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072821

Disclaimer: Curated by HT Syndication.